Edition:
United States

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

11.19USD
14 Dec 2018
Change (% chg)

$-0.51 (-4.36%)
Prev Close
$11.70
Open
$11.68
Day's High
$11.95
Day's Low
$11.10
Volume
38,936
Avg. Vol
26,388
52-wk High
$17.39
52-wk Low
$7.21

Latest Key Developments (Source: Significant Developments)

AC Immune And Lilly Announce License And Collaboration Agreement
Wednesday, 12 Dec 2018 06:30am EST 

Dec 12 (Reuters) - AC Immune SA ::AC IMMUNE AND LILLY ANNOUNCE LICENSE AND COLLABORATION AGREEMENT.AC IMMUNE - MULTI-YEAR DEAL FOCUSES ON MORPHOMER TAU AGGREGATION INHIBITORS, FOR POTENTIAL TREATMENT OF ALZHEIMER'S, OTHER NEURODEGENERATIVE DISEASES.AC IMMUNE - TO RECEIVE AN INITIAL UPFRONT PAYMENT OF CHF 80 MILLION.AC IMMUNE - ELIGIBLE FOR CHF 60 MILLION IN POTENTIAL NEAR-TERM DEVELOPMENT MILESTONES.AC IMMUNE - ELIGIBLE FOR UP TO ABOUT CHF 1.7 BILLION IN OTHER POTENTIAL DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES.AC IMMUNE - LILLY TO PURCHASE $50 MILLION NOTE, CONVERTIBLE TO EQUITY POSITION IN CO.AC IMMUNE - TO CONDUCT INITIAL PHASE 1 DEVELOPMENT OF MORPHOMER TAU AGGREGATION INHIBITORS; LILLY TO FUND, CONDUCT FURTHER CLINICAL DEVELOPMENT.AC IMMUNE - LILLY TO GET WORLDWIDE COMMERCIALIZATION RIGHTS FOR TAU AGGREGATION INHIBITORS IN ALZHEIMER'S DISEASE.AC IMMUNE - RETAINED CERTAIN DEVELOPMENT RIGHTS IN ORPHAN INDICATIONS, CO-DEVELOPMENT, CO-PROMOTION OPTIONS IN CERTAIN INDICATIONS OUTSIDE AD.AC IMMUNE - DEAL TO BE REFLECTED IN LILLY'S GAAP REPORTED RESULTS, FINANCIAL GUIDANCE.AC IMMUNE - NO CHANGE TO LILLY'S 2018 NON-GAAP EARNINGS PER SHARE GUIDANCE AS RESULT OF DEAL.  Full Article

AC Immune Q3 IFRS Loss Per Share CHF 0.21
Tuesday, 13 Nov 2018 04:00am EST 

Nov 13 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q3 REVENUE CHF 2.3 MILLION.Q3 REVENUE VIEW CHF 1 MILLION -- THOMSON REUTERS I/B/E/S.PERIOD END CASH POSITION OF APPROXIMATELY CHF 200 MILLION THAT IS EXPECTED TO EXTEND OUR CASH RUNWAY TO Q3 2021.QTRLY ADJUSTED LOSS PER SHARE CHF 0.18.QTRLY IFRS LOSS PER SHARE CHF 0.21.  Full Article

AC Immune Q2 IFRS Loss Per Share CHF 0.19
Wednesday, 8 Aug 2018 04:00am EDT 

Aug 8 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q2 REVENUE CHF 2.0 MILLION.QTRLY IFRS LOSS PER SHARE - BASIC AND DILUTED CHF 0.19.QTRLY NON-IFRS LOSS PER SHARE - BASIC AND DILUTED CHF 0.19.  Full Article

AC Immune Announces Offerings And Issuance Of Up To 10 Mln Common Shares
Tuesday, 17 Jul 2018 04:09pm EDT 

July 17 (Reuters) - AC Immune SA ::AC IMMUNE ANNOUNCES OFFERINGS AND ISSUANCE OF UP TO 10 MILLION COMMON SHARES.AC IMMUNE SA - COMMENCING OFFERINGS OF UP TO 10 MILLION NEW COMMON SHARES OF CO WITH A NOMINAL VALUE OF CHF 0.02 EACH.AC IMMUNE SA - INTENDS TO ISSUE ALL NEW COMMON SHARES AGAINST CASH CONTRIBUTIONS AS APPROVED BY COMPANY'S SHAREHOLDERS.AC IMMUNE SA - PLANS TO USE PROCEEDS FROM OFFERINGS PRIMARILY TO FUND RESEARCH & DEVELOPMENT EXPENSES FOR CO'S CLINICAL AND PRE-CLINICAL RESEARCH.  Full Article

AC Immune Reports Q1 Revenue CHF 1.5 Million
Wednesday, 2 May 2018 04:00am EDT 

May 2 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q1 REVENUE CHF 1.5 MILLION.Q1 REVENUE VIEW CHF 2 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NON-IFRS EPS LOSS CHF 0.19.  Full Article

AC Immune SA reports quarterly ‍loss per share CHF 0.15
Monday, 13 Nov 2017 06:52am EST 

Nov 13 (Reuters) - AC Immune SA ::AC Immune SA reports third quarter 2017 financial results and corporate update.AC Immune SA qtrly ‍loss per share CHF 0.15 .Says qtrly adjusted loss per share CHF ‍0.16​.  Full Article

AC Immune to get milestone payment for Alzheimer drug
Thursday, 2 Nov 2017 06:36am EDT 

Nov 2 (Reuters) - AC Immune Ltd :Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​.Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​.Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech.  Full Article

AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
Thursday, 2 Nov 2017 06:23am EDT 

Nov 2 (Reuters) - Ac Immune Ltd :AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease.Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017.  Full Article

Essex Bio-Technology enters research project deal with AC Immune
Sunday, 21 May 2017 07:30pm EDT 

May 22 (Reuters) - Essex Bio-technology Ltd <1061.HK>:Company entered into research project agreement with ACI.Deal to collaborate in pre-clinical and clinical co-development of novel biological therapeutic to treat neurodegenerative diseases.  Full Article

Lilly partners with AC Immune for Alzheimer's treatment

U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.